Woodline Partners’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
Woodline Partners's AXSM Position: Q3 2026 in Review
Woodline Partners held its Axsome Therapeutics (AXSM) position steady in Q3 2026 at 162,221 shares worth $29.9M. The position accounts for 0.09% of the portfolio, ranked #297.
Woodline Partners first reported a position in AXSM in Q4 2022 and has held it in 16 quarters since. The position peaked at $44.7M in Q4 2023. 410 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.
- Woodline Partners held 162,221 shares of Axsome Therapeutics worth $29.9M as of Q3 2026.
- Woodline Partners left its Axsome Therapeutics share count unchanged in Q3 2026.
- Axsome Therapeutics made up 0.09% of Woodline Partners's portfolio in Q3 2026, its #297 holding.
- Woodline Partners first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 16 quarters since.
- Woodline Partners's Axsome Therapeutics position peaked at $44.7M in Q4 2023.
- 410 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.